Advances in gene therapy for malignant melanoma

Cancer Control : Journal of the Moffitt Cancer Center
Maria G SotomayorDrew M Pardoll

Abstract

The recent developments in the field of gene transfer have advanced the use of gene therapy as a novel strategy against a variety of human malignancies. Due to its unique set of characteristics, melanoma represents a suitable target for the clinical translation of the different gene transfer approaches recently developed. The goal of gene therapy targeted to melanoma cells is to introduce "suicide" genes, to transfer tumor suppressor genes, to inactivate aberrant oncogene expression, or to introduce genes encoding immunologically relevant molecules. Gene therapy targeted to the host's immune cells has been developed as an additional strategy to redirect immune responses against melanoma. The authors reviewed the published gene transfer studies in experimental models, as well as the results of gene therapy clinical trials for patients with melanoma. Clinical trials have shown the feasibility and safety of gene therapy against malignant melanoma. Although no major successes have been reported, the positive results observed in some patients support the potential for gene therapy in the management of this disease. Gene therapy of melanoma using current gene transfer approaches is feasible and safe. Better vector technology as well ...Continue Reading

References

Aug 1, 1990·Immunological Reviews·B MukherjiM Sivanandham
Nov 27, 1995·International Journal of Cancer. Journal International Du Cancer·C CirielliM C Capogrossi
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R M BlaeseK Culver
Oct 1, 1993·Current Opinion in Immunology·D M Pardoll
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·S L TopalianS A Rosenberg
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·G J NabelA E Chang
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G E PlautzG J Nabel
Mar 1, 1996·Current Opinion in Oncology·S S Agarwala, J M Kirkwood
Aug 1, 1996·The Journal of Experimental Medicine·D BoczkowskiE Gilboa
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A T StopeckS Stahl
Sep 12, 1997·Science·J E Darnell
Nov 14, 1997·Genes & Development·L ChinR A DePinho
Nov 22, 1997·Current Opinion in Immunology·C YeeP D Greenberg
Feb 12, 1998·The Journal of Experimental Medicine·G Schuler, R M Steinman
Feb 5, 1998·Genome Génome / Conseil National De Recherches Canada·G M Arndt, G H Rank
Apr 1, 1998·Nature·J Banchereau, R M Steinman
May 19, 1998·Nature Medicine·D M Pardoll
Jul 31, 1998·Hematology/oncology Clinics of North America·R Gutzmer, D Guerry
Oct 6, 1998·Hematology/oncology Clinics of North America·M B Atkins
Feb 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·H M HortonS E Parker
Jun 17, 1999·FEMS Microbiology Reviews·N K Tanner
Nov 11, 1999·Antisense & Nucleic Acid Drug Development·S D PutneyG Zon
Jun 13, 2000·Oncogene·T BowmanR Jove
Jul 13, 2000·Proceedings of the National Academy of Sciences of the United States of America·T Watanabe, B A Sullenger
Oct 24, 2000·Clinical and Experimental Dermatology·A SchneebergerS N Wagner
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E M JaffeeC J Yeo

❮ Previous
Next ❯

Citations

May 10, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Claudia PenafuerteJacques Galipeau
Jun 6, 2003·Oncogene·María S Soengas, Scott W Lowe
Dec 29, 2004·FEBS Letters·Rosanna Martinelli, Vincenzo De Simone
Jan 25, 2008·Cancer Immunology, Immunotherapy : CII·Claudia Penafuerte, Jacques Galipeau
May 8, 2021·International Journal of Toxicology·Ghazale MinaiyanVajihe Akbari

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.